|
ALIAS
Albumin in Acute Stroke
Ongoing trial
 |
Author(s) |
Hill MD, Moy CS, Palesch YY, Martin R, Dillon CR, Waldman BD, Patterson L, Mendez IM, Ryckborst KJ, Tamariz D, Ginsberg MD |
 |
Title(s) |
The Albumin in Acute Stroke Trial (ALIAS); design and methodology |
|
Reference(s) |
Int J Stroke 2007;2:214–9 |
|
Disease |
Ischaemic stroke |
|
Purpose |
To evaluate the efficacy of high-dose albumin compared to saline control within 5 h of ischaemic stroke onset |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
Up to 12 months |
|
Patients |
Aim 1800 patients, aged ≥ 18 years, with acute ischaemic stroke with a baseline National Institutes of Health Stroke Scale of ≥ 6 |
|
Treatment regimen |
Human serum albumin, high dose of 2 g/kg iv in 2 h, or isovolaemic normal saline |
|
Results |
Not yet available |
|
|
|
